{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lam V"],"funding":["Beckman Research Institute, City of Hope","NCI NIH HHS"],"pagination":["1040-1051"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10525033"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(9)"],"pubmed_abstract":["Novel targeted agents used in therapy of lymphoid malignancies are recognized to have complex immune-mediated effects. Sumoylation, a posttranslational modification of target proteins by small ubiquitin-like modifiers (SUMO), regulates a variety of cellular processes indispensable in immune cell activation. Despite this, the role of sumoylation in T-cell biology in context of cancer is not known. TAK-981 (subasumstat) is a small-molecule inhibitor of the SUMO-activating enzyme (SAE) that forms a covalent adduct with an activated SUMO protein. Using T cells derived from patients with chronic lymphocytic leukemia (CLL), we demonstrate that targeting SAE activates type I IFN response. This is accompanied by largely intact T-cell activation in response to T-cell receptor engagement, with incre"],"journal":["Molecular cancer therapeutics"],"pubmed_title":["T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia."],"pmcid":["PMC10525033"],"funding_grant_id":["P50 CA107399","P50CA107399"],"pubmed_authors":["Siddiqi T","Pennock ND","Roleder C","Danilov AV","Phillips T","Liu T","Berger AJ","Shouse G","Wang L","Lam V","Best S","Bruss N","Alinari L","Wang X"],"additional_accession":[]},"is_claimable":false,"name":"T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.","description":"Novel targeted agents used in therapy of lymphoid malignancies are recognized to have complex immune-mediated effects. Sumoylation, a posttranslational modification of target proteins by small ubiquitin-like modifiers (SUMO), regulates a variety of cellular processes indispensable in immune cell activation. Despite this, the role of sumoylation in T-cell biology in context of cancer is not known. TAK-981 (subasumstat) is a small-molecule inhibitor of the SUMO-activating enzyme (SAE) that forms a covalent adduct with an activated SUMO protein. Using T cells derived from patients with chronic lymphocytic leukemia (CLL), we demonstrate that targeting SAE activates type I IFN response. This is accompanied by largely intact T-cell activation in response to T-cell receptor engagement, with incre","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-04-05T11:39:04.254Z","creation":"2025-04-05T11:39:04.254Z"},"accession":"S-EPMC10525033","cross_references":{"pubmed":["37420267"],"doi":["10.1158/1535-7163.mct-22-0762","10.1158/1535-7163.MCT-22-0762"]}}